Changes of Necroptosis in Irbesartan Medicated Cardioprotection in Diabetic Rats

Changes of Necroptosis in Irbesartan Medicated Cardioprotection in Diabetic Rats

Qingmei Xu,1 Xin Tan,1 Wei Xian,1 Jiayi Geng,2 Haoyu Li,3 Bi Tang,1,4 Heng Zhang,1 Hongju Wang,1,4 Qin Gao,5 Pinfang Kang1,4 1Department of Cardiology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, 233004, People’s Republic of China; 2Department of Preventive Medicine, Beng...

Full description

Bibliographic Details
Main Authors:	Xu Q, Tan X, Xian W, Geng J, Li H, Tang B, Zhang H, Wang H, Gao Q, Kang P
Format:	Article
Language:	English
Published:	Dove Medical Press 2021-09-01
Series:	Diabetes, Metabolic Syndrome and Obesity
Subjects:	cardiomyocyte high glucose irbesartan inflammatory necroptosis
Online Access:	https://www.dovepress.com/changes-of-necroptosis-in-irbesartan-medicated-cardioprotection-in-dia-peer-reviewed-fulltext-article-DMSO

Similar Items

Irbesartan attenuates renal injury with diabetic nephropathy rats
by: ZHANG Ya, HUANG Wen-hui, HOU Zhi-min, LIU Ju-xiang, LIU Jing
Published: (2020-04-01)

Solid lipid nanoparticles of irbesartan: preparation, characterization, optimization and pharmacokinetic studies
by: Deepthi Soma, et al.
Published: (2017-04-01)

Effect of Irbesartan on Chemerin in the Renal Tissues of Diabetic Rats
by: Qiu-Xia Yu, et al.
Published: (2015-09-01)

Comparative bioavailability of a newly developed Irbesartan 300 mg containing preparation
by: Petrov Andrey D., et al.
Published: (2018-01-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Irbesartan; An Antihypertensive Drug Reduces LDL-Cholesterol in Diet Induced Hyperlipidemic Rabbits
by: Sabeen Shakir , Akbar Waheed , Noureen Hafeez
Published: (2016-09-01)

Observational study on patients’ compliance with Irbesartan in essential hypertension “I Comply”
by: K. Leon, et al.
Published: (2014-03-01)

Renoprotective effect of irbesartan in a rat model of gentamicin-induced nephrotoxicity: Role of oxidative stress
by: Hayder M. Al-Kuraishy, et al.
Published: (2019-07-01)

Pharmacokinetic interaction between irbesartan and Orthosiphon stamineus extract in rat plasma
by: Nur Meilis, et al.
Published: (2016-02-01)

HPLC method with monolithic column for simultaneous determination of irbesartan and hydrochlorothiazide in tablets
by: Alanazi Amer M., et al.
Published: (2014-06-01)

Irbesartan eases lipopolysaccharide-induced lung injury In Vitro and In Vivo
by: Zhongyuan Zhang, et al.
Published: (2023-01-01)

Irbesartan attenuates gentamicin-induced nephrotoxicity in rats through modulation of oxidative stress and endogenous antioxidant capacity
by: Hayder M Al-kuraishy, et al.
Published: (2020-01-01)

Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy
by: Noriaki Nagai, et al.
Published: (2022-02-01)

Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients withtype 2 diabetes mellitus and mild hypertension:a sequential, randomized, double-blind clinical trial
by: - Giuseppe Derosa, et al.
Published: (2009-03-01)

Clinical case: Effectiveness of combined therapyOrlistat and Irbesartan at the Metabolic syndrome patient with Arterial hypertension
by: K P Ivanov, et al.
Published: (2009-03-01)

MLKL-mediated necroptosis is a target for cardiac protection in mouse models of type-1 diabetes
by: Ting Cao, et al.
Published: (2022-08-01)

Preparation and Evaluation of Oroslippery Tablets Contain Irbesartan and Hydrochlorothiazide Combination for Dysphagia Patients
by: Yasir Q. almajidi, et al.
Published: (2022-12-01)

Nanocrystalline Suspensions of Irbesartan Enhance Oral Bioavailability by Improving Drug Solubility and Leading Endocytosis Uptake into the Intestine
by: Saori Deguchi, et al.
Published: (2021-09-01)

Study of influence of Catha edulis (Khat) chewing on oral pharmacokinetics of irbesartan in rats using a newly developed HPLC-UV method
by: Hassan A. Alhazmi, et al.
Published: (2022-03-01)

Combined treatment of irbesartan and diltiazem ameliorates endothelium dependent vasodilatation in hypertensives
by: Tingting Zhou, et al.
Published: (2017-10-01)

Efficacy of a fixed dose combination of irbesartan and atorvastatin (Rovelito®) in Korean adults with hypertension and hypercholesterolemia
by: Ihm SH, et al.
Published: (2019-02-01)

Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patierns with type 2 diabetes, hypertension, and renal disease in Switzerland
by: AJ Palmer, et al.
Published: (2006-05-01)

Cyclodextrin Complexed Lipid Nanoparticles of Irbesartan for Oral Applications: Design, Development, and In Vitro Characterization
by: Narendar Dudhipala, et al.
Published: (2021-12-01)

Studies on jackfruit seed starch as a novel natural superdisintegrant for the design and evaluation of irbesartan fast dissolving tablets
by: Vidyadhara Suryadevara, et al.
Published: (2017-09-01)

Effects of irbesartan on phenotypic alterations in monocytes and the inflammatory status of hypertensive patients with left ventricular hypertrophy
by: Jingsi Zhang, et al.
Published: (2021-04-01)

Nuclear translocation of MLKL enhances necroptosis by a RIP1/RIP3-independent mechanism in H9c2 cardiomyoblasts
by: Shoya Ino, et al.
Published: (2023-02-01)

Late-Onset Rash from Irbesartan: An Immunological Reaction
by: Bárbara Kong Cardoso, et al.
Published: (2019-06-01)

Formulation and development of a self-nanoemulsifying drug delivery system of irbesartan
by: Jaydeep Patel, et al.
Published: (2011-01-01)

A Fast and Validated Reversed-Phase HPLC Method for Simultaneous Determination of Simvastatin, Atorvastatin, Telmisartan and Irbesartan in Bulk Drugs and Tablet Formulations
by: Hassan A. Alhazmi, et al.
Published: (2017-12-01)

Downregulation of Mitochondrial Fusion Protein Expression Affords Protection from Canonical Necroptosis in H9c2 Cardiomyoblasts
by: Yuki Toda, et al.
Published: (2024-03-01)

Spectroscopic and in silico approach to probe the binding interactions of irbesartan and human serum albumin
by: Asim Najmi, et al.
Published: (2022-04-01)

Eficacia y seguridad en la vida real de amlodipino/irbesartán en combinación fija en el tratamiento de la hipertensión en América Latina: estudio PARCERIA
by: Álvaro J. Ruiz, et al.
Published: (2023-01-01)

Efficiency assessment for antihypertensive, hemodynamic, renal effects of adenosine-converting enzyme (ACE) inhibitors and irbesartan and impact on endothelial disfunction in patients with stage II hypertension
by: M. V. Pereviazkina
Published: (2014-08-01)

Management of hypertension with fixed-dose combination of irbesartan and amlodipine: A real-life observation
by: Elie Chammas
Published: (2022-01-01)

Immune Activation following Irbesartan Treatment in a Colorectal Cancer Patient: A Case Study
by: E. Titmuss, et al.
Published: (2023-03-01)

Comparison of efficacy and safety between two different irbesartan, generic vs branded, in the treatment of Korean patients with mild-to-moderate hypertension: an 8-week, multicenter, randomized, open-label, Phase IV clinical study
by: Han SH, et al.
Published: (2018-12-01)

Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes
by: Juan He, et al.
Published: (2019-05-01)

Short-term treatment of irbesartan and hydrochlorothiazide decreases plasma N-terminal pro-brain natriuretic peptide levels in subjects with acute exacerbations of COPD
by: Jiang GY, et al.
Published: (2018-12-01)

The combination therapy in arterial hypertension: opportunities of the fixed combination of irbesartan andhydrochlorothiazide(Koaprovel’)
by: O D Ostroumova, et al.
Published: (2014-09-01)

Chronomodulated drug delivery system of Irbesartan: Formulation and development using Desing of Experiment (DoE)
by: Komal Parmar, et al.
Published: (2018-06-01)